Introduction

Mounting evidence has suggested an association of vascular and brain health. Alzheimer’s disease too shares many risk factors with cerebrovascular disease, an observation that has led to the suggestion that cerebrovascular dysfunction and hypoperfusion may play a role in the pathogenesis of neurodegenerative disorders.[1] Recent studies have shown that structural signs of brain aging are also associated with both lowered resting brain perfusion [2] and with general vascular risk factors. [3]

In healthy subjects, large between-subject variability of brain perfusion has been demonstrated, but the knowledge of the biological sources and the possible long-term consequences of this variability is limited.[4] Very recent studies have reported an inverse correlation between cardiovascular risk and measures of cerebral perfusion.[5,6]

In addition to traditional vascular risk factors, also risk factors of arterial aging and endothelial dysfunction have been associated with accelerated structural and functional brain aging. [3] Among several humoral factors associated with endothelial dysfunction, homocysteine is a well-established risk factor for stroke and dementia and has also been associated with structural signs of brain aging. [7–9] The effects of homocysteine and of other risk factors have been suggested to be mediated by the endogenous nitric oxide (NO) synthase inhibitor asymmetric dimethylarginine (ADMA), which has also been demonstrated as an independent risk factor for vascular disease [10] and structural signs of brain aging.[11]

Increased carotid intima-media thickness (IMT), a measure of subclinical atherosclerosis, is also associated with impaired endothelial function and has been reported to correlate with structural brain aging, cognitive decline [5,12] and with regional
brain perfusion changes.[13] Finally, both prior and very recent studies have shown that severe hyperlipidemia may influence cerebrovascular tone by mechanisms unrelated to the proatherogenic properties of hyperlipidemia.[14,15]

Although the above factors are known to influence both vascular function and brain health, their influence on brain perfusion in healthy subjects have not been established. The aim of this study was therefore to investigate the effect of natural variation of these factors on global and regional resting brain perfusion in a cross-sectional population based sample of elderly, healthy subjects. Further, the study should test the hypothesis that risk factors of endothelial dysfunction and atherosclerosis associated with increased risk of degenerative brain disease are also associated with decreased perfusion. Adjusting also for the effects of factors known to influence perfusion, such as hematocrit, carbon dioxide and caffeine, we expect that a significant fraction of the spontaneous variability in resting brain perfusion can be explained by a comprehensive selection of such measurable factors. Overall, the study showed that about half of the variability in brain perfusion could be explained by the factors investigated. Furthermore, it was found that homocysteine in particular was associated with changes in brain perfusion.

Methods

Subjects

Thirty-eight non-smoking subjects 50–75 years of age and in self-reported good health were recruited by newspaper advertisement. Subjects with a history of significant neurological or vascular disease or diabetes, use of neuro- or vasactive medication or oral contraceptives or hormone replacement therapy were excluded from the study. Data relating brain blood flow to cardiac MRI measurements obtained in the same group of subjects have recently been published.[16]

Ethics

The study was approved by the regional ethics committee (Ethics Committee of The Capital Region) following the standards of The National Committee on Health Research Ethics. The experiments were conducted in accordance with the Helsinki Declaration and all subjects gave written informed consent.

Study design

The study was designed as a cross-sectional study with all experimental data for each subject obtained within a single session. On the day of the magnetic resonance imaging (MRI) experiments, the subjects were allowed to both eat and to drink coffee and tea as usual.

All subjects underwent an examination on a separate day prior to the experiment that included fasting blood sampling, ECG, blood pressure, height, weight, carotid Doppler ultrasound including measurement of intima-media thickness and Mini Mental State Examination (MMSE). Subjects with >50% internal carotid artery (ICA) stenosis, blood pressure >160/90 mmHg or fasting plasma cholesterol >7.5 mmol/l were excluded.

MRI experiments

All MRI measurements were performed on a 3.0 T Philips Intera Achieva (Philips Medical Systems, Best, the Netherlands) using a 32 element phased array receive head coil and multi-transmit parallel RF transmission for brain scans.

A high resolution structural scan used for tissue segmentation and calculation of brain volume was obtained using a 3D T1 weighted gradient echo sequence (repetition time (TR) = 10 ms, echo time (TE) = 5 ms, flip angle 8°, matrix 240×200, voxel size 1×1×1 mm, sensitivity encoding (SENSE) factor = 2). To assess brain pathology, standard sagittal and axial T2 weighted scans were acquired in addition to a fluid attenuated inversion recovery (FLAIR) sequence (TR = 11 s, TE = 125 ms, TI = 2.8 s and resolution 0.7×0.8×4 mm).

Total brain blood flow was measured by MRI phase contrast mapping (PCM). Using PCM, volume flow in basilar and the internal carotid arteries (ICAs) can be measured accurately. Normalizing total flow to brain size, mean global brain perfusion can be calculated.[2] PCM measurements were obtained with a matrix of 320×320 (TR = 12 ms, TE = 7 ms, flip angle 10°, voxel size 0.75×0.75×8 mm) with a Vem of 100 cm/s. The sequence was ECG gated (retrospective gating, 20 frames/cycle).

Regional brain perfusion maps were obtained using the Quasar sequence, which is a multi slice, multiple inversion time (TI) pulsed arterial spin labeling (ASL) scheme.[17] General scan parameters were: matrix 80×80, voxel size 3×3×6 mm, gap 1.5 mm, TR/TE/TI/T1 = 4000/22/300/40 ms, flip angle 35°/11.7°, SENSE 2.5, 84 averages (48@Venc = 4 cm/s, 24@Venc = ∞, 12 low flip angle). Seven transaxial slices were acquired parallel to the lower edges of the corpus callosum.

Blood pressure was monitored with a Veris 6600 Vital Signs Monitor (Medrad, Indiana, PA). Expiratory gas was sampled from a mouthpiece and end-tidal Pco2 (PETCO2) was monitored with a Biopac MP150 system (Biopac Systems, Inc., Goleta, CA).

Post-processing

All MRI data were converted into NIfTI format and analyzed using in-house software for Matlab version 7.9 (The MathWorks Inc., Natick, MA) except when indicated otherwise.

Phase contrast mapping. PCM measurements were processed as previously described.[4] Initially an automatic pixel wise phase correction procedure was applied. Then regions of interest for both ICAs and the basilar artery were assigned manually by one investigator and flow was calculated by multiplying mean velocity with vessel area and integrating over time. Brain perfusion is calculated as total brain flow divided by brain volume and reported in mL/100 g/min assuming a tissue density of 1 g/mL.

Arterial spin labeling. ASL data was analyzed using the FSL QUASIL tool applying model-based quantitation.[18] This procedure produces maps of perfusion as well as estimated tissue relaxation rate R1. The perfusion maps were spatially normalized to the MNI standard brain provided by FSL (FMRIB Software Library, www.fmrib.ox.ac.uk/fsl) using an intermediate step in which the R1-images were co registered to the individual high-resolution anatomical scan. In order to obtain relative perfusion maps, perfusion values were normalized to a mean brain perfusion value of 30 mL/100 g/min.

Structural scan. The 3D T1 weighted scan was segmented using the FSL BET and FAST tools. The resulting cerebrospinal fluid (CSF), gray matter and white matter probability maps were used to calculate the total brain tissue volume (V tot), CSF volume (V csf) and brain parenchymal fraction (BPF) calculated as:

\[
BPF = \frac{V_{\text{tot}}}{V_{\text{tot}} + V_{csf}}
\]

Structural scans were reviewed by an experienced neuroradiologist for pathology and severity of white matter lesions using a modified Fazekas rating scale.[19]
Blood samples

Venous blood samples were collected on the day of inclusion and the day of the MRI experiment immediately before commencing the scanning. Blood samples were centrifuged and frozen within 2 hours of sampling and stored at −20°C until analysis.

Fasting blood samples from the day of inclusion were analyzed for plasma lipids, glucose, creatinine, and APOE genotype. The ratio of low density cholesterol to high density lipoprotein cholesterol (LDL:HDL ratio) was calculated as a measure of dyslipidemia.

Venous blood samples were drawn immediately before the MRI scan were analyzed for hematocrit and for plasma concentrations of ADMA, L-arginine, homocysteine and caffeine.

Blood sample analysis. Total plasma homocysteine was determined using an automated latex enhanced immunoassay (Hemosil Homocysteine, Instrumentation Laboratory, Lexington, MA). Intra- and inter-assay CV were 2.9% and 6% respectively.

Asymmetric dimethylarginine (ADMA) and L-arginine were determined by high-performance liquid chromatography with fluorescence detection as previously described using modified chromatographic separation conditions.[20,21] Intra- and inter-assay CV were 1.3% and 2.5%, respectively for arginine, and 1.4% and 2.9%, respectively for ADMA. The Arg:ADMA ratio was calculated because NO production is determined by both substrate availability (arginine) and the presence of inhibitor (ADMA), which may be adequately reflected by this ratio.

In order to characterize the study population genetically, APOE genotype (rs429358 and rs7412 variants) was determined by pyrosequencing using the PyroMark Q24 system (Qiagen, Hilden, Germany) and the following primers: GGAACTGGAGGAAGTCTGA (forward), [Bta]-TACACTGCGAGGGCCGCTCTTCT (reverse) and GCGGACATGGAGGAC (sequencing) for rs429358, and AGCTGCGTAAGCGGCTCCT (forward), [Bta]-C-CGCCGGCCTGGTACACTG (reverse) and CGATGACCTGGAGGAAC (sequencing) for rs4.

Analysis of plasma caffeine was performed using a high-performance liquid chromatography/tandem mass spectrometry method originally developed and validated for analysis of urine samples adapted to analysis of plasma as previously described.[22] Intra- and inter-assay CV were both <7%.

Intima-media thickness

All ultrasound examinations were performed and analysed by the same investigator using a Philips iU22, Ultrasound system (Philips Medical Systems, Best, The Netherlands) equipped with a 3–9 MHz transducer. Long axis B-mode images of the distal part of both common carotid arteries were acquired in three views (anterior, lateral and posterior). IMT was measured at the far wall using dedicated edge detection software (QLAB, Philips Medical Systems, Best, the Netherlands).

Cardiovascular risk

For each subject sex-specific Framingham 10 year cardiovascular event risk was estimated from subject’s age, fasting lipids and blood pressure (measured during the MRI session).[23]

Statistical analysis

Multiple regression analysis was applied for analysis of mean global brain perfusion values. Effects of covariates on regional perfusion were analyzed by applying a general linear model to the spatially normalized perfusion maps. The analysis was performed using in-house software written in Matlab in order to take into account the slightly non-overlapping brain coverage between subjects. Thus, data usage was optimized by including voxels in standard space, even if not all subjects contributed data to that point. Data was thresholded for visualization using a criterion of p<0.001 (uncorrected), cluster size 20 voxels, including only voxels to which at least 10 subjects contributed.

For ordinal data (i.e. WML grade), ordinal logistic regression was applied. Group differences were analyzed using Mann-Whitney test for continuous variables. All statistical analysis was performed using STATA 12 SE (StataCorp, College Station, CA).

Results

Study population characteristics are presented in Table 1.

Global brain perfusion

The effects of the various covariates on brain perfusion in univariate and multiple regression analysis (adjusted for age and sex) are presented in Table 2. Mean brain perfusion was inversely correlated with homocysteine (Figure 1). The effect remained significant after adjustment for age and sex (Table 2), and also when adjusted for hematocrit too (−1.96 [95% CI: −3.79, −0.14] mL/100 g/min per µmol/L, p = 0.036).

Although homocysteine in correlation analysis was positively correlated with both LDL:HDL ratio (r² = 0.11, p = 0.041) and ADMA (r² = 0.13, p = 0.025) and also tended to correlate negatively with Arg:ADMA ratio (r² = 0.10, p = 0.056), neither of these were correlated with brain perfusion (Table 2).

IMT was positively correlated with both age (0.006 [95% CI: 0.001, 0.010] mm per year, p = 0.014) and male sex (0.080 [95% CI: 0.022, 0.138] mm, p = 0.008) in a multiple regression model including both covariates, and was also correlated inversely with Arg:ADMA ratio (r² = 0.16, p = 0.015). No effect of IMT on brain perfusion was observed (Table 2), but including also a sex x IMT interaction in the analysis, a non-significant inverse correlation of IMT with mean global brain perfusion appeared in females only (−50.2 [95% CI: −110.4, 9.9] mL/100 g/min mL in females vs. 22.1 [95% CI: −22.6, 66.7] mL/100 g/min in males, p = 0.099 in females, and p = 0.058 for interaction).

Total brain flow was not different (501 vs. 500 mL/min) in men and women. However, brain perfusion tended to be higher in females than males (52.6 vs. 43.9 mL/100 g/min, p = 0.099) due to differences in brain volume, but no effect of age was observed (Table 2).

Brain perfusion was inversely correlated with hematocrit and caffeine, and positively with PaO₂, (Table 2) Adjusting for hematocrit, no effect of sex on brain perfusion was observed. Table 3 shows the relative effect size of covariates in a multiple regression model including PaO₂, hematocrit, caffeine and homocysteine. This model explained nearly half of brain perfusion variability (unadjusted r² = 0.49). The effects of both homocysteine and of caffeine are larger than or equal to those of hematocrit and PaO₂.

Regional brain perfusion

Analysis of regional brain perfusion maps showed that increasing homocysteine levels were associated with relative parietal hyperperfusion and frontal hyperperfusion. (Figure 2) Neither cardiovascular event risk, Arg:ADMA, LDL:HDL or IMT was associated with regional brain perfusion changes.
Discussion

This study examines the association of risk factors of endothelial dysfunction and atherosclerosis with resting brain perfusion in elderly, healthy subjects. We found an inverse association of homocysteine with brain perfusion, whereas other vascular risk factors did not appear to be major determinants of between-subject brain perfusion variability. Additionally, the study confirms that there is a strong association between brain perfusion and factors such as hematocrit, PCO2 and caffeine. Previously, such associations have been described mainly in interventional studies, whereas the cross-sectional between-subject effects are less well documented.

This is the first report of direct association between homocysteine and brain perfusion in healthy subjects. As most studies of homocysteine lowering treatment have failed to demonstrate any beneficial effect on cardiovascular morbidity and mortality, it has been argued that homocysteine should rather be considered a risk marker than a risk factor of vascular disease. However, long-term treatment has been reported to be effective in primary prevention of stroke [25] and to slow the rate of cerebral atrophy in patients with mild cognitive impairment [26] suggesting that the effects on the brain may differ from those on other organs.

It is not clear how homocysteine exerts its deleterious effects on the brain. Animal and human studies have shown that hyperhomocysteinemia may reduce bioavailability of NO and increases levels of reactive oxygen species [27], leading to endothelial dysfunction [28] and vascular remodeling [29], which in turn causes cerebrovascular resistance to increase. [30] To our knowledge, the present study is the first to show an association of homocysteine levels with brain perfusion, thus supporting cerebral hypoperfusion as a mediator of homocysteine associated cerebral pathology. One previous study involving demented subjects with cobalamin deficiency, reported that brain perfusion increased in patients who responded clinically to cobalamin treatment. Of

Table 1. Subject characteristics.

|                         | Median     | Range          |
|-------------------------|------------|----------------|
| Sex (n = male/female)   | 19/19      |                |
| Age (years)             | 64         | 50–75          |
| Body mass index (kg/m²) | 25.4       | 18.3–34.3      |
| MMSE score              | 29         | 24–30          |
| Total cholesterol (mmol/L) | 5.6       | 3.9–7.5        |
| LDL:HDL ratio           | 2.1        | 0.7–5.7        |
| Intima-media thickness (mm) | 0.69      | 0.5–0.97       |
| Number of APOE4 alleles (0/1/2) | 22/13/3   |                |
| 10 year CV risk score (%) | 12.6      | 3.3–31.3       |
| Brain volume (mL)       | 1086       | 902–1528       |
| Brain parenchymal fraction | 0.738     | 0.701–0.784    |
| Fazekas WML grade (0/1/2/3) | 14/18/5/1 |                |
| Hematocrit (%)          | 44         | 38–55          |
| PCO₂ (kPa)              | 4.42       | 2.83–5.78      |
| Caffeine (µmol/L)       | 17.8       | 0.01–74.2      |
| ADMA (µmol/L)           | 0.43       | 0.33–0.53      |
| Arg:ADMA ratio          | 146        | 47–206         |
| Homocysteine (µmol/L)   | 9.0        | 5.7–13.7       |
| Mean arterial blood pressure (mmHg) | 99 | 79–121 |
| Total flow (mL/min)     | 500        | 307–798        |
| Brain perfusion (mL/100 g/min) | 46.8 | 24.6–67.2 |

Abbreviations: MMSE = mini mental state examination, LDL = low density lipoprotein, HDL = high density lipoprotein, CV = cardiovascular WML = white matter lesion, ADMA = asymmetric dimethylarginine, Arg = L-arginine.

doi:10.1371/journal.pone.0097363.t001

Figure 1. The relationship between homocysteine and global brain perfusion. Dashed line shows line of regression ($r^2 = 0.17$, p = 0.009).
doi:10.1371/journal.pone.0097363.g001
notice, responders also had the higher homocysteine levels than non-responders. [31]

The regional brain perfusion pattern associated with increasing homocysteine shows a relative parietal hypoperfusion and frontal hyperperfusion. The parietal hypoperfusion bears some resemblance with the posterior hypometabolism associated with Alzheimer’s disease and could indicate an early, subclinical manifestation of a neurodegenerative process. More conspicuous is the relative frontal hyperperfusion. Similarly, a recent study showed increased perfusion in parietal, frontal and temporal cortices of healthy APOE4 carriers [32] unlike in demented subjects where the APO4 allele is associated with hypopfusion in the same regions. [33] This phenomenon may be explained as an early adaptive response to capillary flow inhomogeneity in order to maintain tissue oxygenation. [34]

From the present data the mechanism of action cannot be determined, but the findings do not support that homocysteine reduces brain perfusion by an ADMA induced decrease of NO availability. This is in line with findings of a recent study in patients with severe hyperhomocysteinemia due to cystathionine β-synthase deficiency, suggesting that the negative vascular effects of hyperhomocysteinemia have an ADMA-independent etiology. [35]

We did not observe any relation between ADMA or Arg:ADMA ratio with brain perfusion or on structural brain aging in our sample. However, in healthy subjects variability of ADMA is relatively small and unlike most previous studies showing an association of ADMA with vascular disease [10,11], we did not include current smokers and subjects with known hypertension or diabetes. It is thus possible that an effect of ADMA on structural signs of brain aging and possibly also on brain perfusion could be detected in a larger sample also including subjects with a higher vascular risk burden.

No association of general cardiovascular event risk with neither regional nor global brain perfusion was detected. This is most likely due to a relatively small effect size, such that the effect can only be detected in very large samples. [6]

Recent studies reported an association of IMT with both mean global [6] and with regional brain perfusion changes, in particular in females. [13] We did not observe any effect of IMT on mean global or regional brain perfusion. Nor did we observe an effect of HDL:LDL ratio (or of LDL) on mean global or regional brain perfusion. This finding is in line with results from a large study showing no correlation of total brain flow with plasma LDL, total cholesterol or statin treatment. [36]

We observed a negative correlation of caffeine with brain perfusion thus confirming that spontaneous variation in caffeine levels can have large effects on resting brain perfusion and should be taken into account in studies involving measurement of brain perfusion.

Table 2. Effects of covariates on brain perfusion.

|                        | Unadjusted | Adjusted for age and sex |
|------------------------|------------|--------------------------|
|                        | Coef.      | 95% conf. interval       | Coef.      | 95% conf. interval       |
| Age (year)             | −0.257     | −0.768, 0.254            | −0.243     | −0.740, 0.255            |
| Male sex               | −5.55      | −11.8, 0.72              | −5.44      | −11.7, 0.83              |
| Hematocrit (%)         | 1.06†      | −0.99, −0.13             | −1.01†     | −1.95, −0.08             |
| P_{CO2} (kPa)          | 7.16†      | 2.33, 10.06              | 6.88†      | 1.97, 11.79              |
| Caffeine (μmol/L)      | −0.212†    | −0.420, −0.003           | −0.295†    | −0.494, −0.097           |
| LDL:HDL ratio          | −0.24      | −0.67, 0.20              | 0.30       | −0.41, 1.03              |
| Intima-media thickness (mm) | 0.99 | −2.25, 4.22            | 1.93       | −1.27, 5.15              |
| Homocysteine (μmol/L)  | −2.38†+    | −4.13, −0.32             | −2.00†     | −3.86, −0.13             |
| ADMA (μmol/L)          | 10.4       | −50.9, 71.8              | 16.7       | −43.2, 76.6              |
| Arg:ADMA (per 100)     | 0.08       | −9.58, 9.59              | −2.22      | −11.99, 7.54             |

Regression coefficients refer to change in brain perfusion in mL/100 g/min per unit increase of covariate.

*Sex omitted due to co-linearity.

†p<0.05, ††p<0.01 (p-values are not adjusted for multiple comparisons).

Abbreviations: LDL = low density lipoprotein, HDL = high density lipoprotein, ADMA = asymmetric dimethylarginine, Arg = L-arginine.

doi:10.1371/journal.pone.0097363.t002

Table 3. Regression model using standardized regressors.

|                        | Coef.      | 95% conf. interval | p-value | Partial r^2 |
|------------------------|------------|--------------------|---------|-------------|
| Hematocrit (%)         | −2.71      | −5.53, 0.11        | 0.059   | 0.142       |
| Homocysteine (μmol/L)  | −3.61      | −6.59, −0.64       | 0.019   | 0.114       |
| Caffeine (μmol/L)*     | −2.58      | −5.44, 0.29        | 0.076   | 0.101       |
| P_{CO2} (kPa)          | 3.13       | 0.27, 5.99         | 0.033   | 0.170       |
| Intercept (mL/100 g/min)* | 47.4       | 44.8, 50.1         | -       | -           |

*Caffeine levels are not normally distributed, † at mean hematocrit and P_{CO2}.

Vascular Risk Factors and Brain Perfusion
The study also provides some insight into the biological sources of variation of brain perfusion measurements. The combined effects of sex, hematocrit and $P_{ET}CO_2$ may account for only approximately 15% of the spontaneous total between-subject variance.[37] The observation that homocysteine and caffeine may be equally important factors as hematocrit and $P_{ET}CO_2$, significantly adds to the understanding of the factors underlying the variability of brain perfusion. In the model presented in Table 3, the effects of hematocrit and caffeine were no longer significant at the 5% level. As these effects could not be attributed to co-linearity of the covariates, we included also these factors in the final model. The presented model does not imply causality and does not take into account the possible confounding effects of other factors of possible influence.

Study limitations

Accuracy of PCM may be compromised by partial volume effects if in-plane resolution is too low relative vessel diameter (<4–5 pixels) or if the imaging plane is not perpendicular to the vessel.[38] In larger vessels like the ICAs these requirements are usually fulfilled with the imaging protocol used, but partial volume effects may cause inaccuracies of flow measurements in the basilar artery. However, the CBF reported values are in general within the expected range, and the observed correlations of total flow with brain volume and of CBF with gender, hematocrit and $P_{ET}CO_2$ further support the use of PCM for CBF measurements.

The Quasar ASL scheme does not allow whole brain coverage. In order to minimize the effect of flow velocity on labeling, the labeling slab included the circle of Willis. Consequently, the measurements slices did not cover the inferior parts of the brain including the temporal lobes. Finally, the relatively small sample size warrants the findings to be confirmed in future studies.

Perspectives

The association of homocysteine on cerebrovascular function should be investigated in future studies. In that context, it is intriguing why homocysteine and caffeine, which are both associated with reduced brain perfusion, appear to have opposing effects on cerebral health.[39] Future studies should address the effects of caffeine and homocysteine levels on brain perfusion in a stroke population.

Conclusions

The present study adds to our understanding of the sources of brain perfusion variability by showing that homocysteine and brain perfusion co-vary in elderly healthy subjects. These findings have implications for the interpretation of the interplay between vascular risk factors, brain aging and cerebral perfusion.

From the present study, homocysteine may be considered be a marker of altered cerebral perfusion, but the small sample size warrants the findings to be investigated in larger studies, also including diseased subjects and with long term follow-up.

Acknowledgments

The authors wish to thank B. Møller, M. Lindhardt, H. Simonsen, A. Foldager and S. de Jong for practical assistance.

Author Contributions

Conceived and designed the experiments: OH LTJ ER. Performed the experiments: OH. Analyzed the data: PG TT ER OH KK. Contributed reagents/materials/analysis tools: TT PG ER. Wrote the paper: OH. Designed software used: ER. Data analysis: ER OH. Analysis structural MRI: KK. Genetic analysis: PG. Developed and performed ADMA analysis: TT. Conception and design of the study: ER LTJ OH.

References

1. de la Torre JC (2012) Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer’s disease. J Alzheimers Dis 32: 555–567.
2. Vernooij MW, van der Lugt A, Bram M, Wielopolski PA, Vosman HA, et al. (2008) Total cerebral blood flow and total brain perfusion in the general population: the Rotterdam Scan Study. J Cereb Blood Flow Metab 28: 412–419.
3. Cohen RA, Poppas A, Forman DE, Hoth KF, Haley AP, et al. (2009) Vascular and cognitive functions associated with cardiovascular disease in the elderly. J Clin Exp Neuropsychol 31: 98–110.
4. Henriksen OM, Larsson HB, Hansen AE, Gruner JM, Law I, et al. (2012) Estimation of intersubject variability of cerebral blood flow measurements using MRI and positron emission tomography. J Magn Reson Imaging 35: 1290–1299.
5. Pase MP, Grima NA, Stough CK, Scholey A, Pipingas A (2012) Cardiovascular disease risk and cerebral blood flow velocity. Stroke 43: 2803–2805.
6. Jennings JR, Heim AF, Kuan DC, Gianaros PJ, Muldoon MF, et al. (2013) Use of total cerebral blood flow as an imaging biomarker of known cardiovascular risks. Stroke 44: 2480–2485.
7. Seehahi S, Wolf PA, Beiser AS, Selhub J, Au R, et al. (2008) Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 65: 642–649.
8. The Homocysteine Study Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015–2022.
9. Wald DS, Kasturiratne A, Simmonds M (2011) Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement 7: 412–417.
10. Blackwell S (2010) The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 47: 17–28.
11. Notsu Y, Nabiha T, Bokura H, Suyama Y, Kobayashi S, et al. (2009) Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am J Hypertens 22: 257–262.
12. Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR (2009) Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 40: 3180–3185.
13. Sojkova J, Najjar SS, Beason-Held LL, Metter EJ, Davatzikos C, et al. (2010) Intima-media thickness and regional cerebral blood flow in older adults. Stroke 41: 273–279.
14. Rubba P, Facenda F, Di SS, Guazzo A, Scarpato N, et al. (1993) Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia. Stroke 24: 1134–1141.
15. Ayata C, Shim HK, Dilekou E, Atochin DN, Kasibhatla S, et al. (2013) Hyperlipidemia disrupts cerebrovascular reflexes and worsens ischemic perfusion defect. J Cereb Blood Flow Metab.
16. Henriksen OM, Jensen LT, Krabbe K, Larsson HB, Rostrup E (2013) Relationship between cardiac function and resting cerebral blood flow: MRI measurements in healthy elderly subjects. Clin Physiol Funct Imaging: In press.
17. Petersen ET, Lim T, Golay X (2006) Model-free arterial spin labeling quantification approach for perfusion MRI. Magn Reson Med 55: 219–232.
18. Chappell MA, Woolrich MW, Petersen ET, Golay X, Payne SJ (2013) Comparing model-based and model-free analysis methods for QUASAR arterial spin labeling perfusion quantification. Magn Reson Med 69: 1466–1475.
19. Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, et al. (2005) Impact of age-related cerebral white matter changes on the transition to disability — the LADIS study: rationale, design and methodology. Neuroepidemiology 24: 51–62.
20. de Jong T, Teerlink T (2006) Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 353: 287–289.
21. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA (2002) Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303: 131–137.
22. Norager CB, Jensen MB, Weimann A, Madsen MR (2006) Metabolic effects of caffeine ingestion and physical work in 75-year old citizens. A randomized, double-blind, placebo-controlled, cross-over study. Clin Endocrinol (Oxf) 65: 223–229.
23. D’Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743–753.
24. Cacioppo F (2011) Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutic uncertainties. J Thromb Thrombolysis 32: 82–85.
25. Wang X, Qin X, Demirtas H, Li J, Mao G, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369: 1676–1682.
26. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, et al. (2013) Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110: 9523–9528.
27. Zhang F, Shanagha A, Vercellotti GM, Iadecola C (1998) Superoxide-dependent cerebrovascular effects of homocysteine. Am J Physiol 274: R1704–R1711.
28. Stuhlinger MC, Oka RK, Graf EE, Schnodler I, Upson BM, et al. (2003) Endothelial dysfunction induced by hyperhomocysteinemia: role of asymmetric dimethylarginine. Circulation 108: 935–938.
29. Demuth K, Grow M, Girerd X, Moatti J, Paul JF, et al. (2002) Homocysteine is the only plasma thiol associated with carotid artery remodeling. Atherosclerosis 165: 167–174.
30. Lim MH, Cho YI, Jeong SK (2009) Homocysteine and pulsatility index of cerebral arteries. Stroke 40: 3216–3220.
31. Nilsson K, Warkentin S, Halberg B, Fahl R, Gustafson L (2000) Treatment of cobalamin deficiency in dementia, evaluated clinically and with cerebral blood flow measurements. Aging (Milano) 12: 199–207.
32. Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM (2010) APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol 67: 93–98.
33. Cherbuin N, Leach LS, Christensen H, Anstey KJ (2007) Neuroimaging and APOE genotype: a systematic qualitative review. Dement Geriatr Cogn Disord 24: 340–362.
34. Venema PJ, Lammers G, Hartman RH, van Rijn T, Ho YC, et al. (2013) The capillary dysfunction hypothesis of Alzheimer’s disease. Neurobiol Aging 34: 1018–1031.
35. Rocha MS, Teerlink T, Jansen MC, Klaajmans LA, Smulders Y, et al. (2012) Asymmetric dimethylarginine in adults with cystathionine beta-synthase deficiency. Atherosclerosis 222: 509–511.
36. ten Dam VH, Box FM, de Craen AJ, van den Heuvel DM, Bollen EL, et al. (2005) Lack of effect of pravastatin on cerebral blood flow or parenchymal volume loss in elderly at risk for vascular disease. Stroke 36: 1633–1636.
37. Henriksen OM, Krause C, Olsen J, Jensen LT, Larsson HB, et al. (2013) Sources of variability of resting cerebral blood flow in healthy subjects: a study using 133Xe SPECT measurements. J Cereb Blood Flow Metab 33: 787–792.
38. Tan G, Blatter JD, Parker DL (1993) Accuracy of phase-contrast flow measurements in the presence of partial-volume effects. J Magn Reson Imaging 3: 377–385.
39. Eskelinen MH, Kivipelto M (2010) Caffeine as a protective factor in dementia and Alzheimer’s disease. J Alzheimers Dis 20 Suppl 1: S167–S174.